SNAR-I: A Drug Target / Disease Biomarker (G100170222)

Target Name: SNAR-I

NCBI ID: G100170222

Other Name(s): snaR-3 | small NF90 (ILF3) associated RNA I | Small NF90 (ILF3) associated RNA I | SnaR-3

SNAR-I: A Drug Target / Disease Biomarker

SNAR-I, short for Sodium-Glucose cotransporter-I, is a protein that is expressed in most tissues and cells in the body. It is a member of the T-cell antigen 6 (TCA6) family, which is involved in the regulation of cell signaling processes. SNAR-I is primarily localized to the endoplasmic reticulum (ER), where it functions as a transporter for the transport of sodium and glucose across the membrane.

SNAR-I has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are crucial for human health. For example, SNAR-I has been shown to be involved in the regulation of cell signaling pathways that are involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, SNAR-I has also been shown to be a valuable biomarker for the diagnosis and monitoring of various diseases. For example, studies have shown that changes in SNAR-I expression levels can be associated with the development of certain diseases, such as cancer, and that these changes can be detected using qRT-PCR or other molecular assays.

SNAR-I is a protein that is expressed in most tissues and cells in the body. It is a member of the T-cell antigen 6 (TCA6) family and is primarily localized to the endoplasmic reticulum (ER). SNAR-I functions as a transporter for the transport of sodium and glucose across the membrane and has been shown to be involved in the regulation of cellular processes that are crucial for human health. In addition to its potential as a drug target, SNAR-I has also been shown to be a valuable biomarker for the diagnosis and monitoring of various diseases.

Protein Name: Small NF90 (ILF3) Associated RNA I

More Common Targets